Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patients
Susvimo was well tolerated over five years and has a well-characterised safety profile
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with nAMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, MD, PhD, Roche's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.'
'People with nAMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with nAMD for longer in real-world clinical use than IVT injections.'
In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132).
Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort.
The cohort of people who entered the Portal study from Archway is the largest cohort of people with nAMD to be followed prospectively and continuously for five years in a clinical study.1
Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss.
About the Archway study and its open-label extension study (Portal)1,2Archway (NCT03677934) was a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with nAMD. Patients were randomized 3:2 to Susvimo (n = 248) or IVT ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in centre point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing.
About neovascular age-related macular degenerationAge-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading.3 Neovascular or 'wet' AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.4,5 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.5 Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.3,6,7
About Susvimo® (Port Delivery System with ranibizumab)Approved in the United States by the Food and Drug Administration (FDA) for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR), Susvimo is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure.8,9 Susvimo continuously delivers a customised formulation of ranibizumab over time.8,9 Ranibizumab is a VEGF inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.8-10The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab IVT injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat nAMD and other retinal diseases.11
About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
*Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world.
References[1] Kitchens J, et al. Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS. Presented at: The American Society of Retina Specialists (ASRS) 2025 Annual Meeting; 2025 August 01; Long Beach, California, United States.[2] Regillo C, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023;130(7):735-747.[3] Bright Focus Foundation. Age-related macular degeneration (AMD): facts & figures. [Internet; cited July 2025]. Available from: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures [4] Pennington KL, et al. Epidemiology of AMD: associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision. 2016;3:34.[5] Little K, et al. Myofibroblasts in macular fibrosis secondary to nAMD - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-91.[6] Connolly E, et al. Prevalence of AMD associated genetic risk factors and four-year progression data in the Irish population. British Journal of Ophthalmology. 2018 Feb;102:1691-95.[7] Wong WL, et al. Global prevalence of AMD and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014 Feb;2:106-16.[8] US Food and Drug Administration (FDA). Highlights of prescribing information, Susvimo. 2021. [Internet; cited July 2025]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf [9] Holekamp N, et al. Archway randomised phase III trial of the PDS with ranibizumab for neovascular age-related macular degeneration (nAMD). Ophthalmology. 2021.[10] Heier JS, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. The Journal of Retinal and Vitreous Diseases. 2021;41:1-19.[11] US FDA. Highlights of prescribing information, Lucentis. 2012. [Internet; cited April 2025]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf [12] US FDA. Highlights of prescribing information, Vabysmo. 2024. [Internet; cited April 2025]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761235s005lbl.pdf [13] European Medicines Agency. Summary of product characteristics, Vabysmo. [Internet; cited April 2025]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf
Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407 72 58
Sileia UrechPhone: +41 79 935 81 48
Nathalie AltermattPhone: +41 79 771 05 25
Lorena CorfasPhone: +41 79 568 24 95
Simon GoldsboroughPhone: +44 797 32 72 915
Karsten KleinePhone: +41 79 461 86 83
Kirti PandeyPhone: +49 172 6367262
Yvette PetillonPhone: +41 79 961 92 50
Dr Rebekka SchnellPhone: +41 79 205 27 03
Roche Investor Relations
Dr Bruno EschliPhone: +41 61 68-75284e-mail: bruno.eschli@roche.com
Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.com
Dr Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren KalmPhone: +1 650 225 3217e-mail: kalm.loren@gene.com
Attachment
Media Investor Release Susvimo Archway study english
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Time Your Meals, Tune Your Metabolism
New research from UC San Diego has revealed fascinating insights into how timing our meals might significantly affect our metabolic health by aligning with our body's natural microbial rhythms. Just as our bodies follow circadian rhythms, our gut microbes have their own daily patterns, with certain beneficial activities increasing during our active periods to help with digestion and metabolism. The study found that unrestricted access to high-fat foods disrupted these natural patterns, leading to unusual daytime eating and metabolic dysfunction — similar to what human shift workers experience when their eating cycles don't match their biological clocks. Using cutting-edge metatranscriptomics technology, researchers identified a specific enzyme called bile salt hydrolase that plays a crucial role in metabolic improvements. When engineered into beneficial bacteria, this led to increased lean muscle mass, reduced body fat, and better blood glucose regulation. These findings could potentially lead to new targeted therapies for common metabolic disorders, offering hope for those struggling with obesity and diabetes. This breakthrough not only demonstrates the significant influence of circadian rhythms on microbial function, but it also provides a new method for testing how specific microbial activities affect our metabolism through engineered gut bacteria. This content was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Mother of rising motocross star discloses cause of death after fatal mid-race crash
Aidan Zingg, a 16-year-old rising motocross star, died from 'cardiac tamponade,'' his mother, Shari, told USA TODAY Sports. The fatal mid-race crash took place June 28 in Mammoth Lakes, California, and his parents said they hoped autopsy results would help clear up the circumstances around Zingg's death. The Mono County Sheriff's Office is conducting the autopsy of Zingg, who lived with his family in Southern California. Sarah Roberts, public information officer for the Sheriff's Office, said she did not have any information to release. 'The family has the same if not more information, then we have,'' Roberts wrote in an email. Shari Zingg provided no additional information. More: Three young motocross riders have died this year, renewing safety debate The death is being investigated by the Mammoth Lakes Police Department. Zingg is one of three motocross riders 16 or younger who have died this year. In February, a 12-year-old boy died during a motocross crash in Georgia. In June, 2 1/2 weeks before Aidan's death, a 14-year-old boy died after an accident at a motocross practice in North Carolina. What is cardiac tamponade? This is a medical emergency, according to the Cleveland Clinic, which reports a healthcare provider has to remove the extra fluid with a needle or surgery. 'You need quick treatment for a good outcome," according to the Cleveland Clinic. According to the Cleveland Clinic, cardiac tamponade "describes a heart that has so much fluid around it that it can't pump enough blood. The force of this fluid makes it hard for your heart to do its job." Chest trauma is one cause of cardiac tamponade, according to the National Library of Medicine. Zingg suffered chest trauma during the crash, according to Myron Short, who was the race promoter. This article originally appeared on USA TODAY: Mother of rising motocross star discloses cause of death
Yahoo
5 hours ago
- Yahoo
Uptick in stingray injuries in Seal Beach; How you can avoid -- and soothe -- the sting
As Southern Californians enjoy their long summers at the beach, Seal Beach lifeguards are cautioning visitors about the seasonal uptick in stingray-related injuries. In Seal Beach, the average number of stingray stings treated by lifeguards has jumped from one per day to about 10, rising to as many as 15 per day in the last two weeks, said Matthew Corb, marine safety officer for the city of Seal Beach. "We had a long period with not much surf, so there wasn't a lot of swell in the water, and when there isn't a lot of water movement, the ocean gets kind of flat," said Nicholas Bolin, marine safety lieutenant. "That draws stingrays closer to the shore." Stingrays come in at shallower depths because they're more comfortable in calm, warm waters, he said. "When you got hot weather, tons of people at the beach, low tide and not much surf, those are the days where we're seeing that [higher] number," Bolin said. As of Friday afternoon, the lifeguards had treated three stings. Where am I most likely to run into a stingray? The west end of Seal Beach, at the mouth of the San Gabriel River, is known among locals as "ray bay," for its population of — and run-ins with — stingrays. That's because a power plant located a couple of miles inland warms the water, which attracts stingrays, Bolin said. In 2010, it was reported that one-third of nationwide stingray-related injuries were documented at this specific area of the beach. Thirteen years later, the Shark Lab at the California State University, Long Beach, noted that the stingray population was at an all-time high in Seal Beach, with an estimated 30,000 stingrays in the water, ABC News reported. That year researchers said several factors contributed to the population boom, including climate change, better water quality and a decrease in the population of the stingray's predator, white sharks. What kind of fish is a stingray? Stingrays are part of a group of fish known as "batoids" and are closely related to sharks, according to the Shark Lab. Researchers say most stingrays spend their time resting on the seafloor foraging for clams, marine worms, shrimp, isopods, crabs and small fish. A stingray's defense mechanism is to camouflage itself on top of the ocean floor's sand or buried under it. But if stepped on by a human, it will sting, according to California State Parks. The sting comes from the stingray's sharp, barbed stingers on the fish's tails. When the stinger pierces the skin, "it can cause puncture wounds, injection of venom, and tissue damage, leading to pain, swelling, and occasionally secondary infection," according to the state agency. Experts say most stingray-related injuries are reported in the afternoon when the water is warmer and more people are enjoying the ocean. How can I avoid getting stung? To avoid a stingray on the shore, shuffle your feet without picking them up as you move through the water. "You're going to shuffle your feet in the sand until you get out to a point that's deep enough that you can swim or jump on your surfboard," Bolin said. This alerts the buried stingray that you are approaching and gives them a chance to get away, the Shark Lab advises. If you're stung by a stingray, experts recommend soaking the affected area in hot, fresh water for 30 to 90 minutes, or until the pain subsides. Ideally, you'll want to maintain the water temperature at 104 to 113 degrees. The hot water breaks down the stinger venom, relieves the pain of the sting and prevents infection, according to the California State Parks. Aside from the soak, individuals who have been stung are advised to seek medical attention from a healthcare practitioner. When visiting Seal Beach, Bolin recommends checking in with a lifeguard about stingray-related injuries or stingray sightings so you can navigate the ocean safely and enjoy your visit. Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week. This story originally appeared in Los Angeles Times.
